According to the latest NCCN Guidelines for NSCLC (https://www.nccn.org), ROS1 rearrangement and BRAF V600E mutation were newly incorporated into initial gene testing, and the recommendation for PD-L1 detection was strengthened from 2A to 1. Here, CD274 is linked to non-small cell lung carcinoma.